ReviewImmunoHorizons2026
Macrophages in human atherosclerotic plaques in the era of single-cell and spatial transcriptomics.
Review in ImmunoHorizons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrative Single-Cell Transcriptomics, Multi-Omics Analyses, and Computational Pharmacology Reveal Macrophage Heterogeneity and the Putative THBS1-CD36 Axis in Coronary Atherosclerosis.Chemical biology & drug design · 2026Article
- S100A8/A9 and S100A12 Proteins and Macrophage Polarization: Therapeutic Targets in Atherosclerosis.Biomolecules · 2026Review
- Emerging biomedical and pharmaceutical strategies for the treatment of atherosclerosis: from conventional lipid-lowering therapy to nanomedicine.Journal of applied biomedicine · 2026Review
- Cardiac macrophages at the crossroads of inflammation, memory, and repair.ImmunoHorizons · 2026Article
- Inflammatory drivers of carotid atherosclerosis: signaling pathways, immune cells, and plaque stability.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Macrophages are central players of inflammation, lipid metabolism, and remodeling in atherosclerotic plaques. Historically simplified into "M1" and "M2" polarization states, their biology has been fundamentally redefined by single-cell and spatial transcriptomic technologies. Over the past decade, these approaches have identified multiple macrophage subsets within human atheromas, each driven by distinct metabolic and cytokine signatures and occupying discrete spatial niches. Human single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and multimodal omic profiling collectively demonstrate that macrophage subsets extend far beyond fixed polarization states to engage their long-recognized functions in the atheroma, including inflammation, lipid handling and repair. These findings now link macrophage identity to microenvironmental cues, vascular location, and disease stage. Importantly, these data demonstrate that these macrophages do not exist in mutually exclusive states and can transition between these subtypes in response to these aforementioned factors. Here we synthesize these advances, focusing on human data describing macrophage diversity, spatial organization, and metabolic function, and discuss how this knowledge is reshaping mechanistic models of atherosclerosis and the potential therapeutic targeting of macrophage-mediated pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.